Core Viewpoint - The American Academy of Dermatology (AAD) has updated its guidelines, breaking a 23-month revision record, and has strongly recommended the Chinese innovative drug, Zhilimei (Benvimod Ointment), for the treatment of atopic dermatitis (AD) [1][2]. Group 1: Treatment Efficacy - Atopic dermatitis affects approximately 10%-20% of children globally, with patients often relying on hormonal treatments that pose safety and efficacy challenges [2]. - Zhilimei has shown significant clinical value, with 54.4% of patients achieving EASI75 (75% reduction in skin lesions) after 8 weeks, and 46.2% reaching the IGA clinical cure standard [2]. - The response rate in children aged 2-17 years is particularly notable, with an EASI75 response rate of 69.2%, and 83.9% in the 7-11 age group [2]. Group 2: Safety Profile - Zhilimei has a low risk of systemic exposure, with the main adverse reaction being mild folliculitis, which does not require discontinuation of the drug, and no serious adverse events reported [2]. Group 3: Innovation and Market Impact - Zhilimei represents a breakthrough in non-hormonal treatments, achieving rapid, effective, and long-lasting results, especially for pediatric patients [3][4]. - The drug was approved by the Chinese National Medical Products Administration in November 2024 and received FDA approval shortly after, marking a simultaneous launch in both China and the U.S. [4]. - The drug's mechanism targets multiple pathways, overcoming the limitations of traditional therapies that focus on single-point suppression [4]. Group 4: Expert Insights - Experts highlight that Zhilimei addresses key challenges in traditional AD treatments, such as dependency on hormones, nighttime itch control, and long-term efficacy maintenance [5]. - The AAD guideline revision signifies a shift towards "precision treatment" for atopic dermatitis, providing a revolutionary new option for millions of patients worldwide, particularly children [5].